Abstract
Hypotonia, Ataxia, and Delayed Development syndrome is a neurodevelopmental disorder caused by heterozygous Early B-Cell Factor 3 (EBF3) loss-of-function variants. Identified in 2016, the full spectrum of clinical findings and the relationship between the EBF3 genotype and clinical outcomes has not been determined beyond its namesake features. We combined a phenotypic assessment of 33 individuals molecularly diagnosed with EBF3 pathogenic variants with a meta-analysis of 34 previously reported individuals. The combined 62 unique individuals enabled comparative cross-sectional phenotype and genotype analysis in the largest cohort to date of affected individuals. Cardinal distinguishing features were identified that facilitate phenotypic stratification for clinical diagnosis. We developed assessment scales to ascertain individuals at risk for pathogenic EBF3 variants, stratify the clinical severity, and connect variant-specific molecular phenotypes to clinical outcomes. Our findings show that a specific class of EBF3 variants affecting the evolutionarily conserved Zinc Finger (ZNF) motif, which is critical for stabilizing the protein interaction with the DNA target sequence, is associated with an increased risk of persistent motor and language impairments. These findings highlight the impact of combining variant-specific molecular phenotypes with comprehensive clinical data to predict neurodevelopmental outcomes and potentially guide personalized decisions for therapeutic interventions.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
H.T.C. is partially supported from NIH-1DP5OD026428, by the NIH Director High-Risk High-Reward program. C.D. is supported by the Medical Scientist Training Program at BCM. N.D.B. was supported by the Autism Science Foundation. V.L. is supported by The Gordon and Mary Cain Foundation and Annie and Bob Graham. EB and GZ are members of the European Reference Network for Rare Neurological Diseases - Project ID No 739510. EB, EMV, and GZ are supported by the Ministry of Health (Ricerca Corrente 2020, Ricerca Finalizzata NET-2013-02356160). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Individuals were enrolled in a study approved by the Institutional Review Board of Baylor College of Medicine (BCM), following its ethical standards. Written and informed consent was obtained from all individuals before the study was conducted. All procedures followed national standards.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Removed supplemental tables per recommendation from medRxiv team.
Data Availability
De-identified data regarding molecular and clinical findings are available upon request.
